改善子宫内膜癌中错配修复免疫组化异常后的基因检测
本研究回顾性分析2015年7月至2022年5月一家大型城市医院中子宫内膜癌错配修复免疫组化异常的患者,比较2017年4月实施遗传咨询师主动联系医生审批转诊方案前后的遗传咨询转诊率和基因检测率。方案实施后遗传咨询转诊率从68.8%升至96.7%(P=0.02),基因检测率从62.5%升至86.7%(P=0.07),差异未达统计学显著。
要点
- 方案实施后遗传咨询转诊率显著提高(68.8% vs 96.7%,P=0.02)。
- 基因检测率从62.5%升至86.7%,但差异未达统计学显著(P=0.07)。
- 36例接受基因检测的患者中16例(44.4%)确诊林奇综合征。
核心结论
- 改变方案后观察到遗传咨询转诊频率增加,这对患者及其家族具有临床意义。
- 尽管做出额外努力,约15%符合标准者未接受基因检测;作者认为应考虑对子宫内膜癌患者进行通用种系检测。
研究设计与样本
- 回顾性研究,纳入2015年7月至2022年5月一家大型城市医院中错配修复免疫组化异常的子宫内膜癌患者。
- 比较2015年7月至2017年4月(方案前)与2017年5月至2022年5月(方案后)的遗传咨询转诊和基因检测情况,使用卡方检验和Fisher精确检验。
主要发现
- 794例接受免疫组化检测的患者中,177例(22.3%)错配修复结果异常,其中46例(26.0%)符合林奇综合征基因检测筛查标准。
- 46例中,16例(34.8%)在方案实施前识别,30例(65.2%)在方案实施后识别。
- 遗传咨询转诊率从方案前的11/16(68.8%)显著增至方案后的29/30(96.7%),P=0.02。
- 基因检测率在方案前组为10/16(62.5%),方案后组为26/30(86.7%),差异无统计学显著(P=0.07)。
- 36例接受基因检测的患者中,16例(44.4%)确诊林奇综合征:MSH6 9例、MSH2 4例、PMS2 2例、MLH1 1例。
临床怎么用
- 2017年4月起,本研究中心的做法是遗传咨询师获取免疫组化数据并联系医生,为符合林奇综合征筛查标准的患者审批遗传咨询转诊。
- 作者认为应考虑对子宫内膜癌患者进行通用种系检测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Although universal mismatch repair (MMR) immunohistochemistry (IHC) in endometrial cancer began at our institution in July 2015, not all eligible patients were referred for genetic testing (GT). In April 2017, genetic counselors obtained IHC data and contacted physicians to approve genetic counseling referrals (GCRs) for Lynch Syndrome (LS) in eligible patients. We assessed if this protocol increased frequency of GCRs and GT in patients with abnormal MMR IHC. METHODS: We retrospectively (7/2015-5/2022) identified patients with abnormal MMR IHC at a large urban hospital. GCRs and GT were compared between cases from 7/2015-4/2017 (pre-protocol) and 5/2017-5/2022 (post-protocol) with chi-square and Fisher's exact tests. RESULTS: Of 794 patients with IHC testing, 177 (22.3%) had abnormal MMR results with 46 (26.0%) meeting criteria for LS screening with GT. Of 46 patients, 16 (34.8%) were identified prior to and 30 (65.2%) after the protocol initiation. GCRs significantly increased from 11/16 (68.8%) to 29/30 (96.7%) in the pre-protocol versus post-protocol groups, p = 0.02. There was no statistically significant difference in GT between groups (10/16, 62.5% vs 26/30, 86.7%, p = 0.07). Of 36 patients who underwent GT, 16 (44.4%) had LS: MSH6, 9; MSH2, 4; PMS2, 2; MLH1, 1. CONCLUSIONS: Increased frequency of GCRs was observed following the change in protocol, which is important as LS screening has clinical implications for patients and their families. Despite this additional effort, approximately 15% who met criteria did not undergo GT; further efforts such as universal germline testing in patients with endometrial cancer should be considered.
引用
- Karpel HC, Smith M, Brodsky A, et al. Improving genetic testing following abnormal mismatch repair immunohistochemistry results in endometrial cancer. Gynecol Oncol. 2023. PMID: 37290248. doi:10.1016/j.ygyno.2023.04.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。